Buy this Article for $5.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


asthma, COPD, long-acting muscarinic antagonist, tiotropium, inhaled corticosteroid, ICS



  1. Shedd, Glenn Clinton DNP, FNP-BC
  2. Blenis, Robert Colin BSN, RN


Background and purpose: The long-acting muscarinic antagonist tiotropium received an indication for the treatment of asthma from the FDA in 2015.


Methods: This paper summarizes much of the published findings on tiotropium and asthma and explores the heterogeneity of the asthma population vis-a-vis recent changes in guidelines for management of COPD. The accompanying case study provides an illustration of how tiotropium might be added to a patient's regimen appropriately.


Conclusions and implications for practice: Tiotropium has been shown in many studies to be beneficial to patients with asthma as an add-on medication. It should be considered as an agent by the clinician managing patients with both allergic and non-allergic asthma.